argenx to Present at 44th Annual J.P. Morgan Healthcare Conference

Core Insights - Argenx is a global immunology company focused on improving the lives of individuals suffering from severe autoimmune diseases [3] Group 1: Company Overview - Argenx is committed to translating immunology breakthroughs into a portfolio of novel antibody-based medicines [3] - The company has developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker, evaluating its potential in multiple serious autoimmune diseases [3] - Argenx is advancing several earlier stage experimental medicines within its therapeutic franchises [3] Group 2: Upcoming Events - Tim Van Hauwermeiren, the CEO of Argenx, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 8:15 a.m. PT [1] - A live webcast of the presentation will be available on the Investors section of the Argenx website, with a replay accessible for approximately 30 days following the event [2]